Status: Recruiting
NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
The FORTRESS trial (NG-350A-03) is an open-label, single-arm, and multicentre trial of NG-350A in combination with chemoradiotherapy (CRT) in adult patients with locally advanced rectal cancer (LARC) and at least one risk factor for local or distant recurrence.
Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Akamis BioUpdated: Jun 12, 2026Locations: 7
Eligibility criteria
Histologically confirmed adenocarcinoma of the rectum. [+7]
Recurrent rectal cancer. [+12]